Guidelines for Prevention of Progression

Guideline Organization

Sub-topic

CARI-Australia

Prevention of Progression of Kidney Disease
2006

Prevention of Progression of Kidney Disease:

1. Dietary protein restriction
2. Lipids
3. Uric acid
4. Phosphate
5. Exercise
6. Acidosis
7. Erythropoietin
8. Pregnancy
9. Smoking
10. Other agents
11. Other forms of dietary interventions
12. Antihypertensive therapy in diabetic nephropathy
13. ACE inhibitor treatment in diabetic nephropathy
14. Angiotensin II antagonists
15. ACE inhibitor and angiotensin II antagonist combination treatment
16. Protein restriction to prevent the progression of diabetic nephropathy
17. Specific effects of calcium channel blockers in diabetic nephropathy
18. Glucose control and progression of diabetic nephropathy
19. Smoking and the progression of diabetic nephropathy
20. Control of hypercholesterolaemia and progression of diabetic nephropathy
21. Multifactorial therapy and the progression of diabetic nephropathy

Prevention of Progression of Kidney Disease:

1. Analgesic-associated kidney disease
2. Renal artery stenosis
3. Specific management of IgA nephropathy: role of steroid therapy
4. Specific management of IgA nephropathy: role of fish oil
5. Specific management of IgA nephropathy: role of triple therapy and cytotoxictherapy
6. Specific management of IgA nephropathy: role of tonsillectomy
7. Specific management of IgA nephropathy: role of cyclosporin and other therapies
8. Membranous nephropathy: role of alkylating agents
9. Membranous nephropathy: role of steroids
10. Membranous nephropathy: role of cyclosporin therapy
11. Treatment of secondary membranous nephropathy
12. Membranous nephropathy: use of other therapies
13. Reflux nephropathy
14. Focal segmental glomerulosclerosis (FSGS): treatment with steroids
15. Focal segmental glomerulosclerosis (FSGS): use of cyclosporin A
16. Focal segmental glomerulosclerosis (FSGS): cytotoxic therapy
17. Focal segmental glomerulosclerosis (FSGS): correction of secondary causes
18. Focal segmental glomerulosclerosis (FSGS): use of other therapies
19. Blood pressure control: targets
20. Blood pressure control: role of specific anti-hypertensives
21. Reducing proteinuria

CSN-Canada

EBPG-Europe

KDOQI-US

Hypertension and Antihypertensive Agents in Chronic Kidney Disease
(2004)

Hypertension and Antihypertensive agents in Chronic Kidney Disease

• Pharmacological Therapy: Diabetic Kidney Disease
• Pharmacological Therapy: Nondiabetic Kidney Disease
• Pharmacological Therapy: Nondiabetic Kidney Disease
• Pharmacological Therapy: Kidney Disease in the Kidney Transplant Recipient
• Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in CKD

Clinical Practice Guidelines for Diabetes in CKD:

• Management of Hyperglycemia and General Diabetes Care in CKD
• Management of Hypertension in Diabetes and CKD
• Management of Dyslipidemia in Diabetes and CKD
• Nutritional Management in Diabetes and CKD

Clinical Practice Recommendations for Diabetes in CKD:

• Management of Albuminuria in Normotensive Patients with Diabetes and Albuminuria As a Surrogate Marker
• Multifaceted Approach to Intervention in Diabetes and CKD

UK-Renal Association

Module 1: CKD
(2007)

Treatment of Patients with CKD